Trial Profile

An Open-label, Multicenter, Phase I Dose-escalation Study to Assess the Safety, Pharmacokinetic (PK), Immunogenicity and Preliminary Anti-tumor Activity of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ZV 0203 (Primary)
Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; HER2 positive breast cancer; Lung cancer; Solid tumours
Focus Adverse reactions
Sponsors Hangzhou Adcoris Biopharmacy

13 Mar 2025 Planned End Date changed from 7 Jul 2024 to 7 Jul 2025.
04 Jun 2024 Results (As of January 18, 2024, n=15) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
24 Oct 2023 Results (n=15) presented at the 48th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com